Amit Sachdev - Feb 1, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Patient Officer
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 03:24 PM
Previous filing
Nov 16, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +9.8K +30.69% $0.00 41.7K Feb 1, 2022 Direct F1
transaction VRTX Common Stock Award $0 +11.6K +27.87% $0.00 53.4K Feb 1, 2022 Direct F2
transaction VRTX Common Stock Award $0 +8.21K +15.39% $0.00 61.6K Feb 1, 2022 Direct F3
holding VRTX Common Stock 882 Feb 1, 2022 401(k)
holding VRTX Common Stock 15.6K Feb 1, 2022 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
F3 Restricted stock unit award that vests in installments beginning on 02/24/2023.

Remarks:

Exhibit 24 - Power of Attorney